NOVN Novan, Inc.

4.83
-0.11  -2%
Previous Close 4.94
Open 4.94
Price To book 3.81
Market Cap 77.13M
Shares 15,969,000
Volume 85,046
Short Ratio 1.44
Av. Daily Volume 259,010

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released November 29, 2016. Primary endpoint met. End of Phase 2 meeting planned for 2Q 2017 with Phase 3 trials to commence by the end of 2017.
SB206
Human papillomavirus (HPV)
Phase 2 data released April 12, 2017. Primary endpoint met.
SB208
Fungal infections
Phase 3 top-line data released January 27, 2017. Met one of three co-primary endpoints in NI-AC301 trial. Met all endpoints in NI-AC302 trial. Intends to meet with FDA 3Q 2017 regarding a possible NDA submission 1Q 2018.
SB204
Acne vulgaris

Latest News

  1. Durham's Novan stares at company rightsizing, additional financing
  2. Novan reports 1Q loss
  3. Novan Reports First Quarter 2017 Financial Results
  4. Novartis celebrates 21st annual Community Partnership Day with over 24,500 associates volunteering in their local communities
  5. Novartis exercises exclusive option agreement with Conatus for the treatment of NASH
  6. Novartis receives FDA approval for Rydapt® in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of systemic mastocytosis (SM)
  7. Novan Presents Safety Data for SB204 Program
  8. Novan Presents Preclinical Data from Inflammatory Skin Diseases Program
  9. Alcon announces EU launch of CyPass® Micro-Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure (IOP) in patients with primary open-angle glaucoma
  10. Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued
  11. Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the US and Canada
  12. Novartis real-world data at AAN confirms benefit of Gilenya® on four key measures of disease activity in relapsing MS
  13. Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
  14. Novan Gets Positive Phase II Results
  15. Novan's stock rockets after positive trial results
  16. Novan Reports Positive Topline Results with SB208 in Phase 2 Trial
  17. Novartis to strengthen R&D pipeline by in-licensing ECF843 for ophthalmic indications
  18. Novan continues to recruit, adds dermatology advisory council
  19. Novan Welcomes Key Opinion Leaders to New Advisory Council
  20. Why Novan (NOVN) Could Be Positioned for a Surge